MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer

被引：73

作者：

Li, Jiarui ^{[2
]}

Ping, Zhang ^{[2
]}

Ning, Hui ^{[1
]}

机构：

[1] Second Mil Med Univ, Changhai Hosp, Dept Gynecol & Obstet, Shanghai 200433, Peoples R China

[2] Shanghai Jiao Tong Univ, Xin Hua Hosp, Dept Gynecol, Sch Med, Shanghai 200092, Peoples R China

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2012年 / 13卷 / 12期

关键词：

miR-218; cervical cancer; HeLa; cisplatin; MTOR SIGNALING PATHWAY; PHASE-II; MICRORNAS; ACTIVATION; CARCINOMA; INHIBITION; PHOSPHORYLATION; PI3K/AKT/MTOR; SURVIVAL; TARGET;

D O I：

10.3390/ijms131216053

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

MicroRNAs are noncoding RNA molecules of 18-25 nucleotides that regulate gene expression at the post-transcriptional levels. Recent data revealed that miR-218 played key roles in tumor metastasis. Here, we described the regulation and function of miR-218 in cervical cancer. Overexpression of miR-218 reduced the proliferation of the human cervical cancer cell line HeLa and induced cell apoptosis through the AKT-mTOR signaling pathway. In addition, it forced expression of miR-218 suppressed tumor growth in the orthotopic mouse model of HeLa cells. Furthermore, miR-218 increased chemosensitivity to cisplatin (CDDP) in vitro. Our results indicated that targeting miR-218 may provide a strategy for blocking the development of cervical cancer.

引用

页码：16053 / 16064

页数：12

共 34 条

[1] Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature [J].

Anders, Jon C. ;

Grigsby, Perry W. ;

Singh, Anurag K. .

RADIATION ONCOLOGY, 2006, 1 (1)

[2]

Babcock JT, 2011, CURR DRUG TARGETS, V12, P1223

[3] Role of MicroRNAs in Lung Cancer MicroRNA Signatures in Cancer Prognosis [J].

Boeri, Mattia ;

Pastorino, Ugo ;

Sozzi, Gabriella .

CANCER JOURNAL, 2012, 18 (03) :268-274

[4] MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells [J].

Borralho, Pedro M. ;

Kren, Betsy T. ;

Castro, Rui E. ;

da Silva, Isabel B. Moreira ;

Steer, Clifford J. ;

Rodrigues, Cecilia M. P. .

FEBS JOURNAL, 2009, 276 (22) :6689-6700

[5] MicroRNAs as a potential prognostic factor in gastric cancer [J].

Brenner, Baruch ;

Hoshen, Moshe B. ;

Purim, Ofer ;

Ben David, Miriam ;

Ashkenazi, Karin ;

Marshak, Gideon ;

Kundel, Yulia ;

Brenner, Ronen ;

Morgenstern, Sara ;

Halpern, Marisa ;

Rosenfeld, Nitzan ;

Chajut, Ayelet ;

Niv, Yaron ;

Kushnir, Michal .

WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (35) :3976-3985

[6] Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition [J].

Breuleux, Madlaina ;

Klopfenstein, Matthieu ;

Stephan, Christine ;

Doughty, Cheryl A. ;

Barys, Louise ;

Maira, Saveur-Michel ;

Kwiatkowski, David ;

Lane, Heidi A. .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (04) :742-753

[7] Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group [J].

Brewer, CA ;

Blessing, JA ;

Nagourney, RA ;

McMeekin, DS ;

Lele, S ;

Zweizig, SL .

GYNECOLOGIC ONCOLOGY, 2006, 100 (02) :385-388

[8] INVITRO THERMO-CHEMOSENSITIVITY SCREENING OF SPONTANEOUS HUMAN-TUMORS - SIGNIFICANT POTENTIATION FOR CISPLATIN BUT NOT ADRIAMYCIN [J].

CALABRO, A ;

SINGLETARY, SE ;

TUCKER, S ;

BODDIE, A ;

SPITZER, G ;

CAVALIERE, R .

INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (03) :385-390

[9] A PHASE-II STUDY OF IFOSFAMIDE AND CISPLATIN CHEMOTHERAPY FOR METASTATIC OR RELAPSED CARCINOMA OF THE CERVIX [J].

COLEMAN, RE ;

CLARKE, JM ;

SLEVIN, ML ;

SWEETENHAM, J ;

WILLIAMS, CJ ;

BLAKE, P ;

CALMAN, F ;

WILTSHAW, E ;

HARPER, PG .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (01) :52-54

[10] 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways [J].

Guo, C. ;

Gasparian, A. V. ;

Zhuang, Z. ;

Bosykh, D. A. ;

Komar, A. A. ;

Gudkov, A. V. ;

Gurova, K. V. .

ONCOGENE, 2009, 28 (08) :1151-1161

← 1 2 3 4 →